ADVERSE REACTIONS
Hepatic:
Hepatocellular neoplasms and peliosis hepatis have been reported in association with long-term androgenic anabolic steroid therapy (see WARNINGS section).
Genitourinary System:
In men.
- Prepubertal: Phallic enlargement and increased frequency of erections.
- Postpubertal: Inhibition of testicular function, testicular atrophy and oligospermia, impotence, chronic priapism, epididymitis and bladder irritability.
In women: Clitoral enlargement, menstrual irregularities. In both sexes: Increased or decreased libido.
CNS:
Habituation, excitation, insomnia, depression.
Gastrointestinal:
Nausea, vomiting, diarrhea.
Hematologic:
Bleeding in patients on concomitant anticoagulant therapy (see PRECAUTIONS, Drug Interactions).
Breast:
Gynecomastia.
Larynx:
Deepening of the voice in women.
Hair:
Hirsutism and male pattern of baldness in women.
Skin:
Acne (especially in women and prepubertal boys.)
Skeletal:
Premature closure of epiphyses in children (see PRECAUTIONS, Pediatric use).
Fluid and Electrolytes:
Edema, retention of serum electrolytes (sodium, chloride, potassium, phosphate, calcium).
Metabolic/Endocrine:
Decreased glucose tolerance (see PRECAUTIONS, General), increased serum levels of low-density lipoprotein and decreased levels of high-density lipoprotein (see PRECAUTIONS, Laboratory tests), increased creatine and creatinine excretion, increased serum levels of creatinine phosphokinase (CPK). Some virilizing changes in women are irreversible even after prompt discontinuance of therapy and are not prevented by concomitant use of estrogens (see PRECAUTIONS).
|